American Conference Institute (ACI) will be holding its 9th Annual Paragraph IV Disputes conference on April 27-28, 2015 in New York, NY. ACI faculty will provide insights into:
• Teva v. Sandoz and the Impact of a New Claim Construction Standard of Review
• Personal and General Jurisdiction Challenges Under Daimler and Mylan
• Myriad 101 Rejections and Nautilus 112 Indefiniteness Findings
• Barraclude and New Obviousness Considerations
• IPR, CBM, and PGR Utilization in ANDA Litigation
• Reissue Applications as a Cure for Invalidity Findings
• Akamai's Effect on Method of Treatment Claims and Carve-Outs
• Settlement Strategies Post-Actavis
• At-Risk Launches and Damages
The conference will offer presentations on the following topics:
• The Role of Legal Analytics in the Paragraph IV Disputes Landscape: Playing Moneyball for Successful ANDA Litigation Strategy
• Questions of Personal and General Jurisdiction in A Paragraph IV Case: Exploring Daimler's Applicability in a Hatch Waxman Scenario
• Exploring Possible New Grounds Paragraph IV Invalidity Challenges: How 101 Rejections Under Myriad and Findings of 112 Indefiniteness Under Nautilus May Alter Paragraph IV Litigation
• Defeating the Undefeatable: New Obvious Considerations for Paragraph IV Compound Patent Challenges in Light of Baraclude
• PTO Proceedings Retrospect: Exploring the Growing Use of IPR, PGR and CBM Review in Hatch-Waxman Litigation
• Exploring the Utilization of Reissue Applications to Cure Invalidity Findings at the PTAB and District Courts
• The Patent Trial and Appeals Board Live: A Conversation with Administrative Patent Judges on PTAB Practices and Protocols for Hatch-Waxman Practitioners
• A View From the Bench: The Federal Judges Speak
• Teva v. Sandoz -- Claim Construction Redoux: De Novo vs. Deferentia
• Limelight v. Akamai: Assessing Its Impact on Method of Treatment Patents and Section viii Label Carve Outs
• FTC Keynote: Reverse Payment Settlements and Other Antitrust Concerns Impacting Paragraph IV Litigation in the Wake of Actavis
• Developing Practical Strategies for Settling A Paragraph IV Case Post-Actavis: A Litigator's Perspective
• FDA Update: Survey of Agency Activity Impacting Paragraph IV Litigation
• Assessing the True Measure of Damages in At Risk Launch Scenario
• The Ethics of Paragraph IV Practice: New Developments Impacting Professional Responsibility in the Hatch-Waxman Arena
In addition, a pre-conference workshop, entitled "Anatomy of a PTO PTAB Patent Trial in the Hatch-Waxman Arena" will be offered from 8:30 am to 12:30 pm on April 29, 2015.
The agenda for the Paragraph IV Disputes conference can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee for the conference is $2,295 (conference alone) or $2,895 (conference and workshop). Those interested in registering for the conference can do so here, by e-mailing [email protected], by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of the Paragraph IV Disputes conference.
Comments